Last reviewed · How we verify
FF/UMEC/VI (100/62.5/25) mcg
FF/UMEC/VI is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, a long-acting muscarinic antagonist, and an inhaled corticosteroid to reduce airway inflammation and improve bronchodilation in chronic obstructive pulmonary disease.
FF/UMEC/VI is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, a long-acting muscarinic antagonist, and an inhaled corticosteroid to reduce airway inflammation and improve bronchodilation in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | FF/UMEC/VI (100/62.5/25) mcg |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Triple combination inhaler (ICS/LAMA/LABA) |
| Target | Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone furoate (FF) is an inhaled corticosteroid that reduces airway inflammation. Umeclidinium (UMEC) is a long-acting muscarinic antagonist (LAMA) that provides bronchodilation by blocking muscarinic receptors. Vilanterol (VI) is a long-acting beta-2 agonist (LABA) that further enhances bronchodilation. Together, these three agents work synergistically to improve lung function and reduce exacerbations in COPD patients.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nasopharyngitis
Key clinical trials
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design (PHASE4)
- A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FF/UMEC/VI (100/62.5/25) mcg CI brief — competitive landscape report
- FF/UMEC/VI (100/62.5/25) mcg updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI